<DOC>
	<DOCNO>NCT00103168</DOCNO>
	<brief_summary>RATIONALE : Imatinib mesylate may stop growth tumor cell block enzymes need cell growth . Giving imatinib mesylate surgery may kill remain tumor cell . It yet know whether imatinib mesylate effective observation treat gastrointestinal stromal tumor . PURPOSE : This randomized phase III trial study imatinib mesylate see well work compare observation treat patient undergone surgery localize gastrointestinal stromal tumor .</brief_summary>
	<brief_title>Imatinib Mesylate Observation Only Treating Patients Who Have Undergone Surgery Localized Gastrointestinal Stromal Tumor</brief_title>
	<detailed_description>OBJECTIVES : Primary - Compare imatinib monotherapy failure free survival patient two regimen . Secondary - Compare relapse-free survival , relapse-free interval overall survival patient treat regimen . - Determine safety drug patient . OUTLINE : This randomize , open-label , multicenter study . Patients stratify accord participate center , risk category ( high v intermediate ) , tumor site ( gastric v ) , resection level ( R0 v R1 ) . Patients randomize 1 2 arm . - Arm I : Patients receive adjuvant oral imatinib mesylate daily 2 year absence disease progression unacceptable toxicity . - Arm II : Patients observe ( without receive antitumoral therapy ) every 3 month 2 year . After completion study treatment , patient arm I follow every 3 month 2 year . All patient follow every 4 month 3 year least annually thereafter . PROJECTED ACCRUAL : A total 750 patient accrue study within 5 year .</detailed_description>
	<mesh_term>Gastrointestinal Stromal Tumors</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm gastrointestinal stromal tumor Localized disease Meets 1 follow criterion : At highrisk relapse , define 1 follow criterion : Tumor size &gt; 10 cm Mitotic rate &gt; 10/50 highpower field ( HPF ) Tumor size &gt; 5 cm AND mitotic rate &gt; 5/50 HPF At intermediaterisk relapse , define 1 follow criterion : Tumor size &lt; 5 cm AND mitotic rate 610/50 HPF Tumor size 510 cm AND mitotic rate &lt; 5/50 HPF Tumor must stain positive Kit ( CD117 ) polyclonal DAKO antibody stain Must undergone complete resection primary tumor least 2 week , 3 month , study entry Meets criteria 1 follow resection level : R0 ( clear margin ) R1 , define 1 follow criterion : Margins resection contaminate tumor , macroscopic tumor leave behind Intraoperative tumor rupture Shellingout procedure Endoscopic maneuver No residual macroscopic disease surgery Regional positive lymph node allow provide macroscopically excised No distant metastases* , include follow : Peritoneal lesion contiguous primary tumor Liver metastases Hemoperitoneal metastasis NOTE : *Even complete resection ( R0 ) perform PATIENT CHARACTERISTICS : Age 18 Performance status WHO 02 Life expectancy Not specify Hematopoietic Absolute neutrophil count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Hemoglobin ≥ 9 g/dL ( transfusion allow ) Hepatic Bilirubin ≤ 1.5 time upper limit normal ( ULN ) AST ALT ≤ 2.5 time ULN No uncontrolled liver disease No chronic viral hepatitis risk reactivation Renal Creatinine &lt; 1.5 time ULN No uncontrolled chronic renal disease Cardiovascular No New York Heart Association class IIIIV cardiac disease No congestive heart failure No myocardial infarction within past 2 month Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 3 month study participation No uncontrolled diabetes No uncontrolled active infection No HIV infection No psychological , familial , sociological , geographical condition would preclude study compliance participation No severe and/or uncontrolled medical disease No malignancy within past 5 year except adequately treat basal cell squamous cell skin cancer carcinoma situ cervix PRIOR CONCURRENT THERAPY : Biologic therapy No prior molecular target biologic therapy No concurrent filgrastim ( GCSF ) sargramostim ( GMCSF ) support blood count No concurrent anticancer biologic agent Chemotherapy No prior chemotherapy gastrointestinal stromal tumor No concurrent anticancer chemotherapy Endocrine therapy Not specify Radiotherapy No prior radiotherapy No concurrent anticancer radiotherapy Surgery See Disease Characteristics Prior noncurative surgery allow ( e.g. , surgery main diagnostic intent emergency surgery symptomatic intent ) Other No prior imatinib mesylate No prior randomization study No concurrent therapeutic anticoagulation coumarin derivative Concurrent therapeutic lowmolecular weight heparin minidose coumarin derivative ( equivalent oral warfarin 1 mg/day ) allow prophylaxis central venous catheter thrombosis No concurrent antitumoral therapy No concurrent anticancer agents No concurrent investigational drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>gastrointestinal stromal tumor</keyword>
</DOC>